Acoustic Neuroma: Diagnostic and Treatment Approach
MRI with gadolinium contrast is the definitive diagnostic test for acoustic neuroma, and treatment should be stratified by tumor size: observation or stereotactic radiosurgery (SRS) for small asymptomatic tumors, SRS preferred over surgery for small-to-medium symptomatic tumors when preserving facial nerve and hearing function is paramount, and surgical resection mandatory for large tumors (>3 cm) with brainstem compression. 1
Diagnosis
Clinical Presentation
Suspect acoustic neuroma in patients presenting with:
- Unilateral or asymmetric sensorineural hearing loss (most common)
- Unilateral tinnitus
- Vestibular symptoms (dizziness, imbalance)
- Facial nerve dysfunction (rare, suggests advanced disease)
Diagnostic Workup
- MRI with gadolinium enhancement is the gold standard diagnostic test 1, 2
- Pure tone audiometry should be performed initially to document hearing status 3
- Auditory brainstem responses (ABR) can detect tumors with high sensitivity but MRI remains definitive 3
- Histological verification is not always required when imaging is characteristic 1
Treatment Algorithm by Tumor Size
Small Asymptomatic Tumors (Koos Grades I-II)
Observation is the management of choice for small, asymptomatic tumors with normal cranial nerve function 1. This carries evidence level III, recommendation level C.
Alternative: Stereotactic radiosurgery can be performed to stop tumor growth and preserve long-term nerve function, though there remains a small risk of functional deterioration (evidence level II, recommendation level B) 1.
Surgery is NOT recommended in asymptomatic patients due to considerable risk (up to 50%) of functional deterioration despite the goal of cure 1.
Small Tumors with Complete Hearing Loss (Koos Grades I-II)
The treatment hierarchy:
- Observation is usually first-line since no hearing function is at risk (evidence level III, recommendation level C) 1
- SRS is preferred over surgery if tumor control is the goal, as it carries lower risk to facial nerve function (evidence level II, recommendation level B) 1
- Surgery can provide cure but has higher complication risk
Medium-Sized Tumors (Koos Grades III-IV, <3 cm)
Both surgery and SRS are recommended at similar levels (recommendation level C) 1. The decision requires careful discussion with the patient:
- SRS advantages: Lower risk profile than surgery, particularly for facial nerve and hearing preservation 1
- Surgery advantages: Complete tumor removal possible
- Hybrid approach: Subtotal resection to preserve function followed by SRS for growing remnant is a valid option 1
Key evidence: Five prospective studies demonstrate SRS is superior to microsurgery for tumors <3 cm in preserving facial nerve and hearing function 1.
Large Tumors with Brainstem Compression (Koos Grade IV, >3 cm)
Surgery is mandatory as the only option for brainstem decompression 1. These patients typically present with:
- Eighth cranial nerve symptoms
- Facial nerve paresis
- Gait ataxia
Post-surgical options include SRS or observation for any residual tumor 1.
Surgical Approaches (When Surgery is Indicated)
No single approach is superior—choice depends on tumor characteristics and surgeon expertise 1. The three main approaches:
1. Retrosigmoid (Suboccipital) Approach
- Indications: Tumors primarily in cerebellopontine cistern or with significant mass effect
- Advantages: Allows hearing preservation; suitable for various tumor sizes
- Limitations: Limited access to internal auditory canal fundus 1
2. Translabyrinthine Approach
- Indications: Any tumor size when hearing preservation is not a goal
- Advantages: Excellent facial nerve visualization; no brain retraction needed
- Disadvantages: Complete hearing loss inevitable 1
3. Middle Fossa Approach
- Indications: Small tumors (<1 cm intracranial diameter) with hearing preservation goal
- Advantages: Best hearing preservation outcomes for small tumors
- Limitations: Requires careful patient selection; increased facial nerve manipulation 1
Surgical Principles
- Intraoperative neurophysiological monitoring is mandatory for facial nerve preservation 1
- Goal is gross total resection (GTR) when safely achievable—recurrence rates: GTR 3.8%, near-total resection 9.4%, subtotal resection 27.6% 1
- Surgery should be performed at high-volume centers due to experience-outcome correlation 1
Radiosurgery Specifications
- Dose: 11-14 Gy single fraction for SRS 1
- Upper limit: Mass effect on brainstem (Koos IV) is generally considered the cutoff 1
- Technique: No outcome difference between GammaKnife and linear accelerator approaches 1
- Fractionated radiotherapy: Reserved for larger tumors requiring fractionation 1
Management of Recurrence
For recurrence after surgery: Radiosurgery is preferred over reoperation due to lower facial nerve injury risk (evidence level III, recommendation level C) 1
For recurrence after radiosurgery: Both reoperation and radiosurgical retreatment are possible, though surgery carries higher facial nerve risk after prior radiation 1
Follow-Up Protocol
- Years 1-5: Annual MRI and audiometry 1
- After 5 years of stability: Intervals can be doubled 1
- After gross total resection: MRI at postoperative, 2,5, and 10 years 1
Critical Pitfalls to Avoid
- Do not perform surgery on small asymptomatic tumors—observation or SRS preferred 1
- Do not choose translabyrinthine approach if hearing preservation is desired 1
- Do not skip intraoperative monitoring—it improves functional outcomes 1
- Do not assume all residual tumor will grow—only minority progress after intentional subtotal resection 1
Multidisciplinary Approach
Patients should be discussed in multidisciplinary tumor boards involving neurosurgery, ENT surgery, and radiation oncology, particularly for medium-sized tumors where multiple treatment options exist 1.